CD81 and B-cell non-Hodgkin lymphoma: Vences-Catalán et al. and colleagues (2019) revealed that CD81 was upregulated in B cell lymphoma, and targeting CD81 with 5A6 (the anti-CD81 mAb) inhibited lymphoma in vivo and in vitro (Küppers, 2019).